

## ElELYso (taliglucerase alfa)

Effective Date: January 1, 2021

Number: MG.MM.PH.226

### Medical Guideline Disclaimer

Property of EmblemHealth. All rights reserved. The treating physician or primary care provider must submit to EmblemHealth the clinical evidence that the patient meets the criteria for the treatment or surgical procedure. Without this documentation and information, EmblemHealth will not be able to properly review the request for prior authorization. The clinical review criteria expressed below reflects how EmblemHealth determines whether certain services or supplies are medically necessary. EmblemHealth established the clinical review criteria based upon a review of currently available clinical information (including clinical outcome studies in the peer-reviewed published medical literature, regulatory status of the technology, evidence-based guidelines of public health and health research agencies, evidence-based guidelines and positions of leading national health professional organizations, views of physicians practicing in relevant clinical areas, and other relevant factors). EmblemHealth expressly reserves the right to revise these conclusions as clinical information changes, and welcomes further relevant information. Each benefit program defines which services are covered. The conclusion that a particular service or supply is medically necessary does not constitute a representation or warranty that this service or supply is covered and/or paid for by EmblemHealth, as some programs exclude coverage for services or supplies that EmblemHealth considers medically necessary. If there is a discrepancy between this guideline and a member's benefits program, the benefits program will govern. In addition, coverage may be mandated by applicable legal requirements of a state, the Federal Government or the Centers for Medicare & Medicaid Services (CMS) for Medicare and Medicaid members. All coding and web site links are accurate at time of publication. EmblemHealth Services Company LLC, ("EmblemHealth") has adopted the herein policy in providing management, administrative and other services to, EmblemHealth Plan, Inc., EmblemHealth Insurance Company, EmblemHealth Services Company, LLC and Health Insurance Plan of Greater New York (HIP), ConnectiCare, Inc., ConnectiCare Insurance Company, Inc. ConnectiCare Benefits, Inc., and ConnectiCare of Massachusetts, Inc. related to health benefit plans offered by these entities. All of the aforementioned entities are affiliated companies under common control of EmblemHealth Inc.

### Definition

ElELYso is an analogue of  $\beta$ -glucocerebrosidase produced via recombinant DNA technology in genetically modified carrot plant root cells. ElELYso differs from human glucocerebrosidase by two amino acids at the N terminal and seven amino acids at the C terminal end of the protein. ElELYso catalyzes the breakdown of glucocerebroside to glucose and ceramide.

ElELYso is indicated for the treatment of patients with a confirmed diagnosis of Type 1 Gaucher disease.

### Length of Authorization

Coverage will be provided for 12 months

### Dosing

- Each individual dose must not exceed 60 U/kg administered intravenously no more frequently than once every 2 weeks

### Guideline

#### Gaucher Disease, Type 1

- ElELYso is prescribed by or in consultation with a geneticist, endocrinologist, a metabolic disorder sub-specialist, or a physician who specializes in the treatment of lysosomal storage disorders; **AND**
- Patient's diagnosis is established by one of the following:
  - Demonstration of deficient  $\beta$ -glucocerebrosidase activity in leukocytes or fibroblasts; **OR**
  - Molecular genetic testing documenting glucocerebrosidase gene mutation

## Limitations/Exclusions

- Coverage is not recommended for circumstances not listed in the Guideline. Criteria will be updated as new published data are available.

## Applicable Procedure Codes

J3060	Injection, taliglucerase, 200 units
-------	-------------------------------------

## Applicable NDC's

00069-0106-xx	Injection,taliglucerase, 200 unit vial
---------------	----------------------------------------

## Applicable Diagnosis Codes

E75.22	Lipidosis (Gaucher Disease)
--------	-----------------------------

## Revision History

1/1/2021	Criteria apply to Commercial, Medicare, and Medicaid members.
----------	---------------------------------------------------------------

## References

1. Elelyso® for injection [prescribing information]. New York, NY: Pfizer; December 2016.
2. Burrow TA, Barnes S, and Grabowski GA. Prevalence and management of Gaucher disease. *Pediatric Health, Medicine and Therapeutics*. 2011;2:59-73
3. Cox T. Gaucher disease: clinical profile and therapeutic development. *Biologics: Targets & Therapy*. 2010;4:299-313
4. Jmoudiak, M. and Futerman, AH. Gaucher disease: Pathological mechanisms and modern management. *British Journal of Haematology*. 2005;129(2):178–188
5. Grabowski GA. Lysosomal storage disease 1- phenotype, diagnosis, and treatment of Gaucher's disease. *Lancet*. 2008;372:1263-1271.
6. Zimran A. How I treat Gaucher disease. *Blood*. 2011;118:1463-1471.
7. Stirnemann J, Belmatoug N, Camou F, et al. A review of Gaucher disease pathophysiology, clinical presentation and treatments. *Int J Mol Sci*. 2017;18:441.
8. Baris HN, Cohen IJ, Mistry PK. Gaucher disease: The metabolic defect, pathophysiology, phenotypes and natural history. *Pediatr Endocrinol Rev*. 2014;12:72-81.